Hoffmann-La Roche, a global pharmaceutical manufacturer based in Switzerland, announced that it would invest 240 million Swiss francs in the Penzberg biotech center located in Munich, Germany.
According to a press release by the company, the investment will be used for construction of the Diagnostics Operations Complex II. This production facility is scheduled to open in two years and is will lead to 50 new jobs at the biotech center.
The new investment at the Penzberg biotech center is in response to increased global demand for immunoassay testing reagents used in hospitals and laboratories. Immunoassay technology plays a critical role in diagnosing many common diseases. This includes severe health issues like heart disease, hepatitis and cancer.
The new facility will have 26,000 square meters of floor area. According to information from the company, the production facility will consist of a six-story laboratory and two buildings for reagent manufacturing.
In prepared remarks, diagnostics division COO Roland Diggelmann said, “This investment in meeting global demand for immunoassays is further evidence of the success of our personalised healthcare strategy. Today’s diagnostics make it possible to detect and differentiate the causes and triggers of chronic illnesses and acute conditions with greater precision than ever before.” He continued, “The new facility will ensure that we can continue to meet the rising demand for reagents.”
- Effects of Surface Treatment on Hard to Bond Substrates - Supplier Resource
- Sterility Testing Using an Isolator - Webcast
- Selecting and Applying the Right Bag Sealer Technology - Supplier Resource
- Anaheim Learning Labs - Event
- MD&M West - Event
- Medical Design & Manufacturing Executive Summit - Event